Dementia and Alzheimer Disease

Treatment with neflamapimod was associated with statistically significantly higher functional dynamic connectivity, with almost half of the cohort experiencing a greater than 10% increase over time.

Amyloid clearance was achieved by 75% of participants who received remternetug at doses ranging from 700 to 2800 mg IV Q4Q by day 169.

By the end of the open label long-term extension study, BIIB080 reduced aggregated tau pathology in all dose groups assessed across all brain composites.

Investigators exercised caution when considering administration of antithrombotics or a thrombolytic agent for patients on lecanemab as cases of intracerebral hemorrhage of more than 1cm have been observed.

Here's some of what is coming soon to NeurologyLive® this week.

Statistically significant improvements in several quantitative test measures of episodic memory, attentiveness, and depressive emotional bias were observed in patients treated with clenbuterol and nadolol.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease (PD).

Neurology News Network for the week ending April 1, 2023. [WATCH TIME: 4 minutes]

In honor of Traumatic Brain Injury Month, held on March 2023, get caught up on some of the latest news in traumatic brain injury as the NeurologyLive® team shares some of our data updates.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 31, 2023.

Beth McQuiston, MD, RD, neurologist, and medical director at Abbott, shared her initial reaction to the FDA approval of the blood test for traumatic brain injury and a campaign to bring awareness to concussions.

In total, 302 pharmacodynamic changes due to CT1812 were identified, with 11 Alzheimer-related priority biomarkers altered in comparison with placebo.

Despite a pause in the trial due to the COVID-19 pandemic, patients who opted to continue treatment into the open-label extension demonstrated significant improvements in Parkinson disease dementia symptoms for up to 48 weeks.

At the willingness to pay threshold of $200,000 per QALY gained, the estimated annual value for lecanemab was $35,678 and $37,351 from the payer and societal perspectives, respectively.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 24, 2023.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending March 18, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 17, 2023.

Marcus Carstensen, PhD candidate, CTO and co-founder of OptoCeutics in Copenhagen, Denmark, talked about the mechanisms of using noninvasive light technologies for Alzheimer disease treatment.

In honor of Brain Awareness Week, a group of experts in the care of patients with neurological conditions—Ronald C. Petersen, MD, PhD; Brian Grosberg, MD, FAHS; James Beck, PhD; Michael Levy, MD, PhD; Stanley H. Appel, MD —shared their perspectives on hot topics of treatment and management in neurology.

Plasma P-tau217 was associated with cognitive decline across several cognitive tests in 2 different cohorts and with conversion to AD dementia in the large-scale, longitudinal BioFINDER-1 cohort.

Originally approved under the accelerated approval pathway, a final decision on a traditional approval for lecanemab is expected to come in early July.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending March 11, 2023. [WATCH TIME: 3 minutes]